Final results of a Phase 1b study of subcutaneous isatuximab administration by an on-body delivery system (OBDS) plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma (RRMM)
Clinical Lymphoma, Myeloma & Leukemia（2023）
关键词
subcutaneous isatuximab administration,multiple myeloma,relapsed/refractory multiple myeloma,pomalidomide,on-body
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要